INT65166

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 7
Disease Relevance 1.55
Pain Relevance 0.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PLA2G4A) aging (PLA2G4A) Golgi apparatus (PLA2G4A)
endoplasmic reticulum (PLA2G4A) cytoplasmic membrane-bounded vesicle (PLA2G4A) nucleus (PLA2G4A)
Anatomy Link Frequency
myometrium 1
PLB-985 1
PLA2G4A (Homo sapiens)
Pain Link Frequency Relevance Heat
halothane 7 99.42 Very High Very High Very High
Kinase C 1 98.40 Very High Very High Very High
Pain 4 97.12 Very High Very High Very High
Inflammation 76 96.76 Very High Very High Very High
cINOD 13 94.88 High High
sodium channel 1 86.64 High High
diclofenac 3 83.68 Quite High
agonist 4 65.24 Quite High
anesthesia 1 47.24 Quite Low
Dismenorea 1 44.76 Quite Low
Disease Link Frequency Relevance Heat
Drug Induced Neurotoxicity 2 99.42 Very High Very High Very High
Pain 2 97.12 Very High Very High Very High
INFLAMMATION 82 96.76 Very High Very High Very High
Pressure Volume 2 Under Development 1 93.28 High High
Disease 22 86.76 High High
Neurodegenerative Disease 2 85.52 High High
Toxicity 3 75.00 Quite High
Polyps 1 70.08 Quite High
Intestinal Polyps 1 68.92 Quite High
Familial Adenomatous Polyposis 1 66.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This neurotoxicity can be partially blocked by inhibitors of cytosolic phospholipase A2, cGMP-selective phosphodiesterases, or protein kinase C.
Negative_regulation (inhibitors) of cytosolic phospholipase A2 associated with kinase c and drug induced neurotoxicity
1) Confidence 0.57 Published 2000 Journal J. Leukoc. Biol. Section Abstract Doc Link 10648007 Disease Relevance 0.51 Pain Relevance 0.18
It is the first time that SK has been shown to suppress PG production in the myometrium by inhibiting cPLA2 activity.
Negative_regulation (inhibiting) of cPLA2 in myometrium
2) Confidence 0.56 Published 1996 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 8847457 Disease Relevance 0 Pain Relevance 0
Two of these specific GIVA cPLA2 inhibitors were also found to have potent therapeutic effects in animal models of pain and inflammation at dosages well below the control nonsteroidal anti-inflammatory drugs.
Negative_regulation (inhibitors) of cPLA2 associated with pain, inflammation and cinod
3) Confidence 0.39 Published 2007 Journal J. Med. Chem. Section Abstract Doc Link 17672443 Disease Relevance 0.29 Pain Relevance 0.24
We explored the structure-activity relationship of 2-oxoamide-based compounds and GIVA cPLA2 inhibition.
Negative_regulation (inhibition) of cPLA2
4) Confidence 0.39 Published 2007 Journal J. Med. Chem. Section Abstract Doc Link 17672443 Disease Relevance 0 Pain Relevance 0
These effects of halothane were not modified after the inhibition of cytosolic phospholipase A2 by aristolochic acid.
Negative_regulation (inhibition) of cytosolic phospholipase associated with halothane
5) Confidence 0.31 Published 2006 Journal Mol. Pharmacol. Section Abstract Doc Link 16399849 Disease Relevance 0 Pain Relevance 0.32
In response to a variety of soluble and particulate stimuli, NADPH oxidase activation is impaired in cPLA2-deficient, differentiated PLB-985, but addition of arachidonic acid is able to rescue NADPH oxidase activity [139, 140].
Negative_regulation (impaired) of cPLA2 in PLB-985
6) Confidence 0.20 Published 2008 Journal J Leukoc Biol Section Body Doc Link PMC2567897 Disease Relevance 0 Pain Relevance 0.03
Thus, functional impairment or complete loss of cPLA2?
Negative_regulation (loss) of cPLA2
7) Confidence 0.14 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2996791 Disease Relevance 0.75 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox